Back to newsroom

RetinAI enters a multi-year software license agreement with Novartis

Tuesday 31 May 2022

The technology developed by RetinAI is at the crossroads of medical imaging, artificial intelligence, machine learning and early disease detection. | © RetinAI

Building on their existing relationship, Bern-based RetinAI and pharma giant Novartis have entered a long-term collaboration with a multi-year software license agreement for Discovery UNITY.

Based on machine learning and computer vision, RetinAI’s Discovery UNITY platform allows global organizations to aggregate imaging data to improve the understanding of patient populations and outcomes at scale.

The AI capabilities integrated with the platform speed up data processing with expert-level analysis and insights extraction. Customers can thus apply RetinAI’s most advanced tools to support their research and clinical development pipeline in ophthalmology, accelerating data analytics and research workflows.

Companies like Novartis can use RetinAI’s platform to characterize diseases and patient outcomes based on at-scale data organization, data aggregation and applied AI from regulatory-approved and AI research models for diseases in ophthalmology. The platform’s AI models include applications in age-related macular degeneration (including geographic atrophy), diabetic retinopathy, diabetic macular rdema, retinal vein occlusion and glaucoma.

“We are very excited to expand our existing relationship with Novartis and see them as an important partner in implementing the future of digital precision medicine. We believe RetinAI’s UNITY platform will redefine how data analysis is performed in drug development, creating opportunities for more cost-effective, target-based research in discovery and clinical trial design,” said Carlos Ciller, CEO of RetinAI.

The platform is CE-marked and has received clearance from the U.S. Food and Drugs Administration.

Partager sur Twitter Partager sur Facebook Partager sur Whatsapp Partager sur LinkedIn Partager par mail
Back to newsroom

This website uses cookies to improve user experience. More information